Skip to search formSkip to main contentSkip to account menu

MN-029

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Denibulin Hydrochloridedenibulin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and… 
2007
2007
1001 POSTER Assessment of pharmacodynamic effect in a phase I study of MN-029, an IV administered vascular disruptive agent, using dynamic contrast-enhanced MRI
2006
2006
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors.
3096 Background: MN-029 is a novel VDA that binds reversibly to the colchicine-binding site on tubulin and inhibits microtubule… 
2006
2006
359 POSTER Pharmacokinetic and pharmacodynamic effects of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)